PURPOSE
The prognosis for metastatic pancreatic ductal adenocarcinoma (mPDAC) remains dismal. In this multicenter, single-arm, phase II study, we evaluated the combination of serplulimab, gemcitabine plus nab-paclitaxel, and radiotherapy (ICSBR regimen) as first-line treatment for mPDAC patients (ChiCTR2300073237).
M...
K. Cheng, Chen-Yan Zhang, Jia-Xin Liu et al.· Clinical Cancer Research· 0 citations
Hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM) carries a poor prognosis, and treatment options after failure of anti-angiogenic targeted agents combined with immune checkpoint inhibitor (ICI) remain limited.
An adult patient with advanced HCC exhibited primary resistance to three sequent...
Qin Xu, Rui Zhu, Zi-Rui Wang et al.· Journal of Cancer Research a...· 0 citations
A case of a patient with advanced HCC who developed cutaneous, pulmonary, and lymphatic metastases following failure of multiple lines of tyrosine kinase inhibitors including donafenib and regorafenib is presented, highlighting the potential benefit of an EGFR-targeted triplet strategy in refractory HCC with EGFR prote...
Qin Xu, Xiao-Fen Li, Rui Zhu et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.